ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

avatrombopag

Also written as “E5501”, “Avatrombopag” and “Avatrombopag 20 mg Oral Tablet”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic, led by 2 companies.

Drug pageAvatrombopag: every studyAll 52 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 13, 201125 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai180 open or runningphase 3since Sep 13, 2011Feb 27, 2007none ahead
Swedish Orphan Biovitrumits history only71 open or runningphase 4since Nov 11, 2020Oct 27, 2017Jun 30, 2028phase 3 · NCT07786922

Also a collaborator on its studies: CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eisai only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Feb 27, 2007.

  1. Jun 4, 2009Phase 2 study in ThrombocytopeniaNCT00914927 · 130 enrolled · United States
  2. Nov 30, 2010Phase 1 study in Healthy SubjectsNCT01251731 · 36 enrolled · United States
  3. Dec 13, 2010Phase 1 study in Healthy SubjectsNCT01260155 · 16 enrolled · United States
  4. Jan 27, 2011Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT01289509 · 42 enrolled · United States
  5. Mar 30, 2011Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT01327872 · 84 enrolled · Netherlands
  6. May 16, 2011Phase 2 study in ThrombocytopeniaNCT01355289 · 65 enrolled · United States
  7. Sep 13, 20112 phase 3 studies in Purpura, Thrombocytopenic, IdiopathicNCT01433978, NCT01438840
  8. Sep 19, 2011Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT01437384 · 36 enrolled · United States
  9. Dec 6, 2012Phase 1 study in Healthy VolunteersNCT01759394 · 36 enrolled · United States
  10. Jan 18, 2013Phase 1 study in HealthyNCT01774773 · 15 enrolled · Japan
  11. Oct 24, 20132 phase 3 studies in ThrombocytopeniaNCT01976104, NCT01972529
  12. Jan 13, 2014Phase 1 study in ThrombocytopeniaNCT02039076 · 48 enrolled · United States
  13. Aug 26, 2014Phase 2 study in ThrombocytopeniaNCT02227693 · 39 enrolled · Japan
  14. Jun 20, 2016Phase 1 study in Healthy ParticipantsNCT02809768 · 48 enrolled · United States

TargetBeta

MPL →read by rule
“The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, ”NCIt, by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
eltrombopagruleGlaxoSmithKlinephase 449
romiplostimruleAmgenphase 438
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 18 Eisai leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02809768Healthy Participants · United States1CompletedAug 201648
NCT02227693Thrombocytopenia · Japan2CompletedApr 1, 201539
NCT02039076Thrombocytopenia · United States1CompletedJun 201448
NCT01976104Thrombocytopenia · United States, Argentina, Australia and more3CompletedJan 30, 2017204
NCT01972529Thrombocytopenia · United States, Argentina, Australia and more3CompletedJan 26, 2017231
NCT01774773Healthy · Japan1CompletedJul 201315
NCT01759394Healthy Volunteers · United States1CompletedJan 201336
NCT01438840Purpura, Thrombocytopenic, Idiopathic · Australia, Belgium, Bulgaria and more3CompletedNov 201349
NCT01437384Purpura, Thrombocytopenic, Idiopathic · United States1CompletedMar 201236
NCT01433978Purpura, Thrombocytopenic, Idiopathic · United States3TerminatedSep 201324
NCT01355289Thrombocytopenia · United States2CompletedFeb 201465
NCT01327872Purpura, Thrombocytopenic, Idiopathic · Netherlands1CompletedApr 201184
NCT01289509Purpura, Thrombocytopenic, Idiopathic · United States1CompletedMar 201142
NCT01260155Healthy Subjects · United States1CompletedJun 201016
NCT01251731Healthy Subjects · United States1CompletedJan 201136
NCT00914927Thrombocytopenia · United States2CompletedNov 11, 2011130
NCT00625443Purpura, Thrombocytopenic, Idiopathic · United States2CompletedJun 200953
NCT00441090Purpura, Thrombocytopenic, Idiopathic · United States2CompletedJan 200964

How it is read

Names in the registry

  • “E5501”, 9 entries
  • “Avatrombopag”, 8 entries
  • “Avatrombopag 20 mg Oral Tablet”, 2 entries
  • “Avatrombopag Oral Tablet”, 2 entries
  • “avatrombopag”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.